Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.semcancer.2021.02.015
- Scopus: eid_2-s2.0-85101882363
- PMID: 33647386
- WOS: WOS:000803637600002
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Cellular heterogeneity and plasticity in liver cancer
Title | Cellular heterogeneity and plasticity in liver cancer |
---|---|
Authors | |
Keywords | Hepatocellular carcinoma Heterogeneity Plasticity Cancer therapy Liquid biopsy |
Issue Date | 2021 |
Publisher | Academic Press. The Journal's web site is located at http://www.elsevier.com/locate/semcancer |
Citation | Seminars in Cancer Biology, 2021, Epub 2021-02-26 How to Cite? |
Abstract | Hepatocarcinogenesis involves complex genetic and cellular dysregulations which drive the formation of hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, with extensive heterogeneity. In contrast to the broad spectrum of molecularly driven therapies available for defined patient groups in certain cancer types, unfortunately the treatment options for HCC are highly limited. The lack of representative molecular and cellular signatures in the heterogeneous HCC tumors that can effectively guide the choice of the most appropriate treatment among the patients unavoidably limits the treatment outcome. Advancement and wide availability of the next-generation sequencing technologies have empowered us to examine and capture not only the detailed genetic alterations of the HCC cells but also the precise composition of different cell types within the tumor microenvironment and their interactions with the HCC cells at an unprecedented level. The information generated has provided new insight and better defined the inter-patient intertumoral heterogeneity, intra-patient intratumoral heterogeneity as well as the plasticity of HCC cells. These collectively provide a robust scientific basis in guiding the development and use of targeted therapy and immunotherapy. To complement, liquid biopsy coupled with high-sensitivity sequencing could potentially be adopted as a more practical and safer approach to detect and reflect the tumor heterogeneity in HCC patients in guiding the choice of treatment and monitoring disease progression. |
Description | Hybrid open access |
Persistent Identifier | http://hdl.handle.net/10722/298726 |
ISSN | 2023 Impact Factor: 12.1 2023 SCImago Journal Rankings: 3.297 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, LK | - |
dc.contributor.author | Tsui, YM | - |
dc.contributor.author | Ho, DWH | - |
dc.contributor.author | Ng, IOL | - |
dc.date.accessioned | 2021-04-12T03:02:33Z | - |
dc.date.available | 2021-04-12T03:02:33Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Seminars in Cancer Biology, 2021, Epub 2021-02-26 | - |
dc.identifier.issn | 1044-579X | - |
dc.identifier.uri | http://hdl.handle.net/10722/298726 | - |
dc.description | Hybrid open access | - |
dc.description.abstract | Hepatocarcinogenesis involves complex genetic and cellular dysregulations which drive the formation of hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, with extensive heterogeneity. In contrast to the broad spectrum of molecularly driven therapies available for defined patient groups in certain cancer types, unfortunately the treatment options for HCC are highly limited. The lack of representative molecular and cellular signatures in the heterogeneous HCC tumors that can effectively guide the choice of the most appropriate treatment among the patients unavoidably limits the treatment outcome. Advancement and wide availability of the next-generation sequencing technologies have empowered us to examine and capture not only the detailed genetic alterations of the HCC cells but also the precise composition of different cell types within the tumor microenvironment and their interactions with the HCC cells at an unprecedented level. The information generated has provided new insight and better defined the inter-patient intertumoral heterogeneity, intra-patient intratumoral heterogeneity as well as the plasticity of HCC cells. These collectively provide a robust scientific basis in guiding the development and use of targeted therapy and immunotherapy. To complement, liquid biopsy coupled with high-sensitivity sequencing could potentially be adopted as a more practical and safer approach to detect and reflect the tumor heterogeneity in HCC patients in guiding the choice of treatment and monitoring disease progression. | - |
dc.language | eng | - |
dc.publisher | Academic Press. The Journal's web site is located at http://www.elsevier.com/locate/semcancer | - |
dc.relation.ispartof | Seminars in Cancer Biology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Hepatocellular carcinoma | - |
dc.subject | Heterogeneity | - |
dc.subject | Plasticity | - |
dc.subject | Cancer therapy | - |
dc.subject | Liquid biopsy | - |
dc.title | Cellular heterogeneity and plasticity in liver cancer | - |
dc.type | Article | - |
dc.identifier.email | Chan, LK: lkchan1@hku.hk | - |
dc.identifier.email | Tsui, YM: ymtsui@hku.hk | - |
dc.identifier.email | Ho, DWH: dwhho@hku.hk | - |
dc.identifier.email | Ng, IOL: iolng@hku.hk | - |
dc.identifier.authority | Chan, LK=rp02289 | - |
dc.identifier.authority | Ho, DWH=rp02285 | - |
dc.identifier.authority | Ng, IOL=rp00335 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1016/j.semcancer.2021.02.015 | - |
dc.identifier.pmid | 33647386 | - |
dc.identifier.scopus | eid_2-s2.0-85101882363 | - |
dc.identifier.hkuros | 321977 | - |
dc.identifier.volume | Epub 2021-02-26 | - |
dc.identifier.isi | WOS:000803637600002 | - |
dc.publisher.place | United Kingdom | - |